» Articles » PMID: 34546342

The Cortisol Response of Male and Female Choroidal Endothelial Cells: Implications for Central Serous Chorioretinopathy

Overview
Specialty Endocrinology
Date 2021 Sep 21
PMID 34546342
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Context: Central serous chorioretinopathy (CSC) is a severe ocular disease characterized by fluid accumulation under the retina and abnormalities in the underlying vascular layer, the choroid. CSC has a striking prevalence in males of 80% to 90% of total patients. Corticosteroids are the most pronounced extrinsic risk factor for CSC. Choroidal endothelial cells (CECs) are important for the vascular integrity of the choroid, but the effects of corticosteroid effects in these cells are unknown.

Objective: We aimed to reveal the potential steroidal contribution to CSC.

Method: We characterized the expression of the glucocorticoid, mineralocorticoid, and androgen receptor in the human choroid using immunohistochemistry. Using RNA-sequencing, we describe the cortisol response in human CECs derived from 5 male and 5 female postmortem donors.

Results: The glucocorticoid receptor was highly expressed in the human choroid, whereas no to minimal expression of the mineralocorticoid and androgen receptors was observed. The extensive transcriptional response to cortisol in human primary cultured CECs showed interindividual differences but very few sex differences. Several highly regulated genes such as ZBTB16 (log2 fold change males 7.9; females 6.2) provide strong links to choroidal vascular regulation.

Conclusions: The glucocorticoid receptor predominantly mediates the response to cortisol in human CECs. Interindividual differences are an important determinant regarding the cortisol response in human cultured CECs, whereas intrinsic sex differences appear less pronounced. The marked response of particular target genes in endothelial cells to cortisol, such as ZBTB16, warrants further investigation into their potential role in the pathophysiology of CSC and other vascular conditions.

Citing Articles

Differential Expression of Sex-Steroid Receptors in the Choroid Aligns With Central Serous Chorioretinopathy Sex Prevalence Across Different Ages.

Galuh S, Meijer O, Brinks J, Schlingemann R, Boon C, Verdijk R Invest Ophthalmol Vis Sci. 2024; 65(8):5.

PMID: 38958971 PMC: 11223622. DOI: 10.1167/iovs.65.8.5.


Choroidal arterial abnormality in central serous chorioretinopathy.

Tuuminen R, Jeon S Graefes Arch Clin Exp Ophthalmol. 2024; 262(11):3465-3473.

PMID: 38748212 DOI: 10.1007/s00417-024-06522-w.


Overlap of Genetic Loci for Central Serous Chorioretinopathy With Age-Related Macular Degeneration.

Ramo J, Abner E, van Dijk E, Wang X, Brinks J, Nikopensius T JAMA Ophthalmol. 2023; 141(5):449-457.

PMID: 37079300 PMC: 10119776. DOI: 10.1001/jamaophthalmol.2023.0706.


Risk of Central Serous Chorioretinopathy in Male Androgen Abusers.

Subhi Y, Windfeld-Mathiasen J, Horwitz A, Horwitz H Ophthalmol Ther. 2023; 12(2):1073-1080.

PMID: 36692812 PMC: 10011293. DOI: 10.1007/s40123-023-00658-4.


Central serous chorioretinopathy: Pathophysiology, systemic associations, and a novel etiological classification.

Jain M, Mohan S, van Dijk E Taiwan J Ophthalmol. 2023; 12(4):381-393.

PMID: 36660127 PMC: 9843580. DOI: 10.4103/2211-5056.362601.


References
1.
Nicholson B, Atchison E, Idris A, Bakri S . Central serous chorioretinopathy and glucocorticoids: an update on evidence for association. Surv Ophthalmol. 2017; 63(1):1-8. DOI: 10.1016/j.survophthal.2017.06.008. View

2.
Zalachoras I, Verhoeve S, Toonen L, van Weert L, van Vlodrop A, Mol I . Isoform switching of steroid receptor co-activator-1 attenuates glucocorticoid-induced anxiogenic amygdala CRH expression. Mol Psychiatry. 2016; 21(12):1733-1739. DOI: 10.1038/mp.2016.16. View

3.
Haimovici R, Rumelt S, Melby J . Endocrine abnormalities in patients with central serous chorioretinopathy. Ophthalmology. 2003; 110(4):698-703. DOI: 10.1016/S0161-6420(02)01975-9. View

4.
Lotery A, Sivaprasad S, OConnell A, Harris R, Culliford L, Ellis L . Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. Lancet. 2020; 395(10220):294-303. DOI: 10.1016/S0140-6736(19)32981-2. View

5.
Hsu Y, Chen Y, Chen T, Sue Y, Cheng T, Chen J . Far-infrared therapy induces the nuclear translocation of PLZF which inhibits VEGF-induced proliferation in human umbilical vein endothelial cells. PLoS One. 2012; 7(1):e30674. PMC: 3264594. DOI: 10.1371/journal.pone.0030674. View